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Dr. Ryan discusses patient with Thomas Deering, M.D. , Evans cardiology fellow. (Photo by Bradford F. 
Herzog) 
For AHA's president a key 
question is, "How many 
patients will benefit?" 
Thomas J. Ryan, M . D . , has become president 
of the Amer ican Eieart Association at what 
is, by any measure, a stormy period i n the 
evolut ion of heart disease research and treat-
ment . 
He assumed the post i n November 1984, 
shortly after the Baby Fae case and the na-
tion's second art i f ic ia l heart implanta t ion 
had put cardiology i n the l i m e l i g h t as never 
before. A n d the succeeding implantat ions 
this winter , w i t h more expected, suggest that 
the controversy surrounding the experimen-
tal techniques is l i k e l y to continue through 
his term. (As the result of a change i n the 
Association's "year," he w i l l remain presi-
dent u n t i l June 1986.) 
Dr. Ryan, head of the Evans Section of 
Cardiology and Univers i ty Elospital's ehief of 
cardiology, makes clear that he is not op-
posed to the attention-gett ing technologies 
per se. 
"The emerging transplant technology, the 
development of art i f ic ia l hearts, the consid-
eration of interspecies transplants: These are 
all mountains that have to be c l imbed, " says 
Dr. Ryan. "Ever since Leonardo da Vinc i con-
cluded that the heart functions pretty m u c h 
l ike a motor, man has been down i n the 
basement t ry ing to invent a replacement for 
that motor, and such efforts have got to go 
forward . " 
On the other hand, he does not l ike some 
of the methods being used. He says, for ex-
ample, that Baby Fae would have had a bet-
ter chance w i t h corrective surgery. As for the 
art i f ic ial heart program, he is dismayed w i t h 
the way Humana, Inc., is conducting i t . 
"There's absolutely no question that i n -
dustry should support biomedical research, 
and the medical c o m m u n i t y should encour-
age that support ," says Dr. Ryan. " O n the 
other hand, I do not believe i t is appropriate 
for a company to serve as the sponsor, judge 
Continued on page 5 
'Ever since Leonardo 
da Vinci concluded 
that the heart func-
tions pretty much like 
a motor, man has 
been down in the 
basement trying to in-
vent a replacement 
for that motor and 
these efforts have got 
to go forward.' 
U N I V E R S I T Y H O S P I EAL 
at Boston Universi ty 
Medical Center 
Cardiology's research is 
marked by concern with 
clinical usefulness 
The Evans Section of Cardiology, under the 
direct ion of Thomas J. Ryan, M . D . , has a 
broad-ranging research program marked by a 
concern w i t h advances that w i l l be c l inieal ly 
relevant for significant numbers of patients. 
The program has a history of significant 
contributions to the field. One of its major 
contributions of the last decade, for example, 
stemmed f r o m a longstanding interest among 
Section investigators i n sophisticated mea-
surements of left ventricular func t ion both at 
rest and under conditions of stress, such as 
that associated w i t h isometric exercise or al-
tered body chemistry. 
That act ivity, carried out i n the catheteri-
zation lab, led to some of the first studies of 
a new f a m i l y of drugs called converting en-
zyme inhibi tors for patients w i t h congestive 
heart failure. As a result of these pioneering 
studies, the drug captopril is now widely 
used i n treating heart failure patients. 
A m o n g more recent interests are: 
• N e w pacemaker designs. This project, un-
der Paul Levine, M . D . , is aimed at producing 
a pacemaker that controls both the left 
a t r i u m and left ventricle, and has feedback 
systems so that its pulses are precisely keyed 
to the heart's requirements. 
• A r t i f i c i a l intelligence systems i n the Car-
diac Care U n i t . Investigators under Michael 
Klein , M . D . , and Robert Friedman, M . D . , are 
w o r k i n g on new computer-controlled sys-
tems that, by drawing upon data f r o m the 
ECG and other sources, can help cardiolo-
gists make better short-term prognoses for 
heart patients i n cr i t ical condit ion. 
• Heart w a l l - m o t i o n studies. Using sophisti-
cated new echocardiographic equipment, Ev-
ans cardiologists led by Edgar C. Schick Jr., 
M . D . , are developing innovative ways to use 
the analysis of w a l l - m o t i o n patterns i n mak-
ing diagnoses and prognoses. 
This is but a sampling of the Section's re-
search ini t iat ives . A selected group of addi-
t ional studies is described i n more detail i n 
the stories that fo l low. 
/. Laser angioplasty: 
Overcoming the obstacles 
Laser angioplasty has generated a lot of head-
lines but so far has not proven its value i n 
treating coronary artery disease. The basic 
reason lies i n some realities about using las-
ers w i t h i n the narrow and delicate confines 
of a eoronary artery. 
" A number of investigators have shown 
that you can vaporize atherosclerotic lesions 
w i t h a laser beam," notes T i m o t h y A . San-
born, M . D . , associate director of the Cardio-
vascular Research Laboratory. "The problem 
is to figure out how to control the fiber t ip 
so that you can safely remove the plaque 
w i t h o u t perforating the vessel w a l l . " 
One of the more exotic proposed solutions 
is to have an imaging capacity i n the cathe-
ter that transmits the laser. Dr. Sanborn's 
group is experimenting w i t h a system i n 
w h i c h a T V image is conveyed through an 
optic fiber i n the catheter, so that the car-
diologist can see exactly how the catheter is 
positioned i n the artery. 
To work , however, this arrangement re-
quires four different channels i n the catheter: 
one for the laser, one for the T V signal, one 
for a l ight to i l l u m i n a t e the plaque, and one 
for a saline solut ion to f lush blood f r o m the 
site. This means that the catheters have to 
be at least 2.5 m m i n diameter. The four-
channel system, therefore, has promise i n 
treating atherosclerotic lesions i n the periph-
eral arteries, but is too large for treating le-
sions i n the coronary arteries, where the l u -
men may be I m m or less. 
As a result. Dr. Sanborn says, his group's 
m a i n focus has been on another approach: 
changing the method of delivering the laser 
energy so that i t can be safely used w i t h only 
a fluoroscopic image of the site. 
"We've been w o r k i n g w i t h a modif ied 
f o r m of the optic fiber t i p , " he explains. " I t 's 
made of stainless steel, and it 's designed so 
that when the laser strikes i t , the laser en-
ergy is converted to heat energy and distrib-
uted c ircumferential ly w i t h i n the artery. By 
doing that you have a margin of safety, be-
cause you're not focusing a lot of energy on 
one p o i n t . " 
A key consideration is the amount of heat 
generated, and the investigators have found 
that delivering heat at about 400 degrees C. 
seems to be effective i n removing lesions i n 
lab animals. 
"We've demonstrated that i t can remove 
plaque w i t h o u t damaging healthy tissues," 
says the cardiologist, "and now we're looking 
at longterm consequences. We have seen 
some closing up of the vessels after the pro-
cedure, but our numbers are similar to what 
Dr. Sanborn, right, holds 
optic fiber with low-power 
argon laser beam being 
transmitted through it. 
With him is Dr. Faxon. Tip 
is submerged in water in 
order to prevent it from 
overheating. (Photo by 
Bradford F. Herzog) 
New fiber tip, which dis-
tributes laser's energy cir-
cumferentially rather than 
focusing it on a single 
point. 
r 
happens w i t h balloon angioplasty." 
The next step w i l l be to t ry the procedure 
i n patients w i t h disease of the peripheral ar-
teries. N o schedule has been set for that 
phase of the work , says Dr. Sanborn, but he 
expects to start seeking appropriate candi-
dates w i t h i n the next year or so. 
//. Balloon angioplasty: 
A bid to cut failure rates 
Balloon angioplasty, once restricted to pa-
tients w i t h a single arterial blockage, is now 
rout inely performed i n patients w i t h m u l t i -
ple blockages. 
I t is, moreover, no longer l i m i t e d to 
younger patients. I n fact, says Evans investi-
gator David P. Eaxon, M . D . , there is growing 
evidence that many patients i n their 60s and 
70s do better than younger patients. 
I n addition, cardiologists have concluded 
that repeat procedures are safe. Dr. Eaxon, 
w h o heads U H ' s Cardiac Catheterization 
Laboratory, says he has repeated the proce-
dure as many as f ive times i n a single pa-
t ient . 
Yet w h i l e balloon angioplasty has ad-
vanced w e l l beyond the experimental phase, 
the rate at w h i c h arterial blockages recur—a 
process called restenosis—has held steady at 
between 20 and 30 percent. 
I n many cases, of course, angioplasty can 
be repeated. Then, the major problem associ-
ated w i t h the restenosis is cost. But the high 
risk associated w i t h restenosis i n certain ar-
teries has deterred eardiologists f r o m even 
t r y i n g the procedure i n such vessels. 
" M o s t cardiologists w o n ' t perform balloon 
angioplasty i n the left m a i n coronary," notes 
Dr. Faxon. "That 's part ly because it 's r isky 
and part ly because experience suggests there 
is a high m o r t a l i t y rate that is apparently 
due to a sudden onset of restenosis." 
Dr. Faxon's group has done animal experi-
ments aimed at p inpoint ing the causes of 
restenosis. Their w o r k indicates that a plate-
let bui ldup i n the hours immediate ly fo l low-
ing angioplasty is the key problem. 
"We've found that there is a very marked 
platelet adhesion at the angioplasty in jury 
site i n the artery," notes Dr. Faxon. " N o w , 
what we'd l ike to do is to derive the rela-
t ionship between the number of platelets 
la id down and the l ike l ihood of restenosis." 
That phase of the research w i l l have to 
w a i t u n t i l the group has validated a new 
technique for radioactively tagging the plate-
lets. Meanwhile , though, the investigators 
also are planning tests of agents that may 
block the platelet buildups. 
"Agents l ike aspirin and persantine are 
rout inely used i n patients after balloon an-
gioplasty," says Dr. Faxon, " b u t a lot of ex-
periments suggest that these agents aren't 
very effective. They do affect the platelets, 
yes, but they don't signifieantly prevent the 
platelets f r o m adhering to the artery w a l l . " 
As a result, the group is starting to test a 
variety of experimental drugs. Early results 
of this w o r k suggest that one of the more 
promising of the new agents is a thrombox-
ane synthetase inhib i tor . 
"Thromboxane is a prostaglandin that's 
present i n the platelets, and thromboxane 
synthetase seems to start the prostaglandin 
cascade that results i n platelets having the 
abi l i ty to adhere to the lesion site," says Dr. 
Faxon. " O u r findings so far suggest that this 
agent does a pretty good job of preventing 
the cascade f r o m getting started." 
Balloon catheter tip used in angioplasty. 
///. Clinical trials: A long 
and productive tradition 
N o medical discipline has embraced large-
scale c l inical trials as enthusiastically as car-
diology and few major teaching hospitals 
have taken part i n as many of these trials as 
Univers i ty Hospital . 
Currently, for example, the Hospital is par-
t ic ipat ing i n the w i n d - u p phase of the Coro-
nary Artery Surgery Study (CASS) and getting 
ready for the m a i n phase of the Thrombo-
lysis i n Myocardial Infarct ion (TIMI) study. 
The CASS project has given an especially 
strong boost to the concept of mult icenter 
trials, says Dr. Thomas Ryan, principal i n -
vestigator at Univers i ty Hospital for that and 
other trials. 
The study, l ike al l the major trials, is 
sponsored by the Nat iona l Heart, Lung and 
Blood Inst i tute . I t was launched i n 1975 i n 
response to questions about whether patients 
w h o have coronary artery disease but exhibit 
few or no symptoms benefit f r o m bypass sur-
gery. A tota l of 11 ins t i tut ions took part, and 
780 patients were enrolled. Half were given 
bypass operations, the other half not. 
" A n earlier European study concluded that 
people w h o have three-vessel disease always 
benefit f r o m bypass surgery," notes Dr. Ryan. 
" W h e n we looked at i t , we found that that 
was not always so. The key f inding was that 
i t depended on whether they had normal 
ventricular func t ion or not. Those w i t h nor-
mal func t ion did no better w i t h surgery, 
whereas those w i t h abnormal funct ion did 
better w h e n treated surgically than w i t h con-
t inued medical therapy." 
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Research indicates 
that platelet buildups 
in the hours following 
angioplasty are the 
main reason block-
ages recur. 
The CASS project, w h i l e a milestone of 
sorts among major heart-related studies, is 
s t i l l only one of many such trials. I n fact, the 
earliest of t h e m dates back to 1960. 
That i n i t i a l t r ia l , aimed at testing the l i p i d 
hypothesis, involved administrat ion of five 
agents that were thought to slow atheroscler-
otic bui ldups or to reduce serum cholesterol 
levels. Robert W i l k i n s , M . D . , former director 
of the Evans, was one of the principal archi-
tects of that study. 
A l t h o u g h the t r i a l produced results that 
were inconclusive at best, i t provided valu-
able lessons on h o w to design major c l inical 
trials. Partly as a result, recent trials have 
been designed w i t h an eye to providing clear 
guidance on controversial issues i n cardiol-
ogy-
The T I M I study, for example, is aimed at 
c lar i fying the value of a new heart-attack 
therapy that is already i n wide use. 
"There's an a w f u l lot of thrombolyt ic ther-
apy being done based on some early reports 
that i t helps heart-attack patients," says Dr. 
Merle A . Kel let t , assistant director of UH's 
Cardiac Catheterizat ion Laboratory and an 
assistant professor of medicine. "We have yet 
to establish, however, whether i t increases 
survival i n the weeks and months fol lowing 
the attack." 
The t r ia l , w h i c h involves a total of 13 cen-
ters, w i l l enrol l roughly 3,500 patients. Tis-
sue plasminogen activator (t-PA), a protein 
that mobil izes an enzyme, plasmin, that at-
tacks the f i b r i n i n clots, w i l l be administered 
to half the patients. The other half w i l l get a 
placebo. 
T-PA was chosen after a prel iminary t r ia l 
i n w h i c h i t demonstrated better efficacy at 
dissolving clots than the other agent tested, 
streptokinase. T-PA is also believed to pro-
duce fewer serious side effects, l ike heavy 
bleeding, than other thrombolyt i c agents. 
IV. Treadmill test: Aiding 
heart-disease prognosis 
Roughly f ive years ago, Evans investigators 
dealt a b l o w to the usefulness of the tread-
m i l l test i n diagnosing coronary artery dis-
ease. 
Using data f r o m the Coronary Artery Sur-
gery Study (CASS), the investigators com-
pared the standard t r e a d m i l l exercise test 
w i t h other diagnostic measures. CASS pro-
vided t h e m w i t h a large study sample, since 
5,000 of the 25,000 patients screened for i n -
clusion i n that t r i a l underwent exercise 
stress tests. 
"We found that the test was not as useful 
as previously t h o u g h t , " says Donald A. Wei-
ner, M . D . , a member of the Evans Section of 
Cardiology and one of the lead investigators 
i n this CASS offshoot. "The test showed a 
re l iabi l i ty rate of about 70 percent, and its 
abi l i ty to improve on w h a t could be learned 
f rom s imply t a l k i n g to the patient or taking 
the history wasn' t that great." 
The research group, however, also wanted 
to explore the exercise test's value i n prog-
nosis. 
"We fol lowed the study populat ion for five 
years, and we were quite surprised by what 
we f o u n d , " says Dr. Weiner, also an associate 
professor of medicine at BUSM. "We were 
able to define t w o very dist inct groups 
w i t h i n the study populat ion. One was a low-
risk subset that included about one-third of 
the patients. I t was made up of people who 
were able to f in i sh the t h i r d stage of the 
t readmil l test and showed no signs of is-
chemia. They had a five-year m o r t a l i t y rate 
of about 5 percent. 
"Another, higher r isk subset—about one-
eighth of the study population—comprised 
those patients w h o could not get through the 
first phase of the test and did have signs of 
ischemia. Their five-year m o r t a l i t y rate was 
roughly 27 percent." 
The results, says Dr. Weiner, suggest that 
patients whose t readmi l l results are good 
probably have a good prognosis on their pres-
ent regimens, w h i l e those whose results are 
poor may be candidates for more aggressive 
treatment. 
Dr. Weiner and his colleagues plan to con-
tinue f o l l o w i n g the study group through the 
tenth year f o l l o w i n g the CASS screenings. 
Meanwhile , one finding that has emerged 
f rom their research is that the exercise stress 
test may have a significant, though special-
ized, role i n diagnosis after a l l . 
"We're not just interested i n whether there 
is disease, but also i n where a patient fits i n 
terms of risk s trat i f icat ion," notes Dr. Wei-
ner. "We're finding that w h i l e the exercise 
test does not help m u c h i n assessing whether 
there is disease, i t can help clarify the r isk 
profiles of patients w i t h disease. That means 
that you can use the test as a sereening 
mechanism—for example, to help assess 
whether a patient m i g h t need catheteriza-
t ion, or whether the patient w h o has a par-
t icularly strenuous job should consider mak-
ing a s w i t c h . " • 
Dr. Weiner and technician 
Maria Filancia check 
patient's performance 
on treadmill. (Photo 
by Bradford F. Herzog) 
'The test showed a 
reliability rate of 
about 70 percent and 
its ability to improve 
on what could be 
learned from simply 
talking to the patient 
or taking the history 
wasn't that great' 
Ryan. 
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and jury on a research project. That's never 
going to w o r k . There is a way for this to be 
done right , and that is to involve outside 
peer groups i n a review of what the investi-
gators should do next . " 
More generally, he says that cardiology 
must strike a balance among a range of dif-
ferent approaches to heart problems. 
"Some of these technological innovations 
are coming on l i k e cyclones, and they are 
very seductive i n their appeal, but there are 
other important aspects of cardiology—pre-
vention, c l inical trials, the whole new field 
of the molecular biology of heart disease— 
and we cannot lose sight of t h e m , " says the 
cardiologist, also a professor of medicine at 
Boston Univers i ty School of Medicine. 
Discernible i n Dr. Ryan's refiections on 
the state of cardiology is the theme that the 
effort put i n t o devising a new therapy or de-
veloping a new technology must be carefully 
measured against its potential value i n help-
ing patients. That theme is not surprising i n 
someone long k n o w n for his concern w i t h 
patient care. The same theme, i n fact, can be 
readily traced i n the evolut ion of his career. 
For example, one of Dr. Ryan's first inter-
ests was the use of catheterization i n diagno-
sis. 
" W h e n I was a medical student back i n the 
'50s, cardiac catheterization was just assum-
ing its preeminence as the u l t imate means 
by w h i c h to establish any given diagnosis of 
heart disease," he says. " L i k e any medical 
student, I was quite enamored of the stetho-
scope and a l l i t could te l l me about a pa-
tient's heart. I guess m y greatest learning ex-
perience was p u t t i n g the findings of m y l i t t l e 
stethoseope against the giant of cardiac cath-
eterization—it was the gold standard then, as 
i t is now—and perhaps this explains m y con-
t i n u i n g fondness for both modes of diagno-
sis." 
Early catheterization efforts were restricted 
to measuring heart funct ion , not imaging the 
heart or the arteries. St i l l , says Dr. Ryan, the 
catheter did help to ident i fy candidates for 
existing surgical procedures for the heart, 
w h i c h included operations for valve disease 
caused by rheumatic fever as w e l l as for con-
genital defects l i k e coarctation of the aorta. 
I n the early 1960s, when Dr. Ryan was 
chief of cardiology at St. Elizabeth's Hospital 
i n Boston, his cardiac catheterization lab be-
came only the second one i n the c i ty to per-
f o r m coronary angiography. 
Other ini t iat ives instigated or supported by 
Dr. Ryan as his career has evolved bear at 
least a philosophical resemblance to his early 
promot ion of the cath lab. They do not re-
veal resistance to technological innovation, 
as his Section's current research on laser 
technology, angioplasty and pacemakers at-
tests; but they do show that a deeper con-
cern is, "What does this study or this tech-
nique mean i n terms of patient care?" 
He mentions, for example, the Section's 
exercise stress study, w h i c h lets cardiologists 
make prognoses for heart-attack v ic t ims sim-
Dr. Ryan with head nurse Janet Eagan, R .N. , in 
University Hospital's Cardiac Care Unit . (Photo by 
Bradford F. Herzog) 
ply by using the t readmil l test. A n d he notes 
w i t h particular pride the major, mult icenter 
c l inical trials his Section has taken part i n : a 
beta blocker t r ia l , the Coronary Artery Sur-
gery Study (CASS) and the Thrombolysis i n 
Myocardial Infarct ion (TIMI) study, among 
others. (Stories on some of the trials and on 
other research interests of the Section may 
be found starting on page 2.) 
Such studies can have a major impact 
upon patient care. The CASS project, w h i c h 
indicated that not a l l patients w i t h signifi-
cant coronary artery disease need bypass sur-
gery, is a case i n point . 
I n addition, suggests Dr. Ryan, they have a 
valuable impact on the participating ins t i tu -
tions. "These studies improve the level of 
cooperation among participating depart-
ments , " he says, "and they inject a certain 
discipline i n t o the acquisit ion and recording 
of data. I t h i n k that on the whole, they help 
to foster a very high caliber of care." 
Asked his thoughts about the longterm 
outlook for his discipline. Dr. Ryan says he 
believes the prospects for real progress are 
bright. Areas of particular promise, he adds, 
include prevention and molecular biology. 
"We cardiologists t h i n k we k n o w what we 
mean by ischemia, and at one level we do," 
he says. "But there's a lot going on w i t h i n 
each of the cells that are affected by a heart 
attack, too. We have got to begin w o r k i n g 
m u c h more closely w i t h the molecular biolo-
gists to understand what those changes are." 
A n d prevention? "The annual physical 
exam, instead of being a defensive activity, 
has got to become an offensive one," says Dr. 
Ryan. " I t h i n k the patient should sit down 
w i t h his physician periodically, and review 
where they are i n their efforts to reduce 
k n o w n risk factors for cardiovascular disease, 
and what they should be doing next . " • 
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For Dr. Ryan, technol-
ogies like artificial 
hearts and inter-spe-
cies transplants merit 
study, but only if the 
research has a firm, 
scientific foundation. 
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Evans/Transition 
Cont inu ing past patterns, most of the 1984 
graduates of the Evans residency program at 
Univers i ty Hospital chose to go on for addi-
t ional t ra ining i n a suhspeciality, w h i l e some 
entered private practice. 
The graduates, and their career pursuits, 
are: 
Carolyn Bondy, M.D. , endocrinology. Na-
t ional Institutes of Heal th 
Mark Drapek, M.D., private practice, Wake-
field, Mass. 
Maria Fiatarone, M.D., geriatrics. Univers i ty 
of California at Los Angeles 
Jonathan Fletcher, M.D., chief resident. U n i -
versity Hospital 
Joseph Frank, M.D. , oncology, Nat iona l Can-
cer Inst i tute 
Robert Galvin, M.D., private practice. Pea-
body, Mass. 
Douglas Galasko, M.D., neurology, Johns 
Hopkins Hospital 
Steve Heibrunn, M.D., cardiology, Stanford 
Medical Center 
Heidi Jolson, M.D. , private practice, Dorch-
ester, Mass. 
Donald Milton, M.D., occupational health. 
Harvard School of Public Heal th 
Thomas Morris, M.D. , pulmonary medicine, 
Massachusetts General Hospital 
Edward Murphy, M.D., epidemiology. Na-
t ional Cancer Inst i tute 
Andrew Villanueva, M.D. , pulmonary medi-
cine. Univers i ty Hospital 
Alan Wagshal, M.D. , cardiology. Univers i ty 
Hospital . 
This year's Evans' interns at Univers i ty 
Hospital , and the medical schools f r o m 
w h i c h they graduated, are: 
Brian Ardel, M.D., Boston Univers i ty 
Leslie Blackball, M.D., N e w York Univers i ty 
Harvey Carp, M.D. , M i a m i Univers i ty 
John Costa, M.D., M o u n t Sinai 
Bernadine Donahue, M.D. , Boston Univers i ty 
Renee Goetzler, M.D., Boston Univers i ty 
Richard Hartoch, M.D., Washington Univer-
sity 
Robert Joseph, M.D., Boston Univers i ty 
Kenneth Krutt, M.D., N e w York Medical 
College 
Kenneth Lader, M.D., Univers i ty of Massa-
chusetts 
Jeffrey Mulhern, M.D., N e w Jersey Medical 
School 
Harry Peled, M.D., Alber t Einstein 
Mark Rudberg, M.D., Wiseonsin Medical 
College 
Ira Shocket, M.D., Univers i ty of Virginia 
Jerome Sobieraj, M.D., Wayne State Univer-
sity 
Jack Stroh, M.D., Alber t Einstein 
Douglas Weiner, M.D., Boston University. • 
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Noteworthy 
• Aram V. Chobanian, M.D., chief of the 
Section of Hypertension and Atherosclerosis 
and a professor of medicine, is chairman-
elect of the A H A ' s Counci l on H i g h Blood 
Pressure and president-elect of the N e w Eng-
land Cardiovascular Society. Charles Tifft, 
M.D., a member of the same Section and an 
associate professor of medicine, is president-
elect of the A H A ' s Greater Boston Div i s ion . 
• "The Complete Book of Medical Tests," 
w r i t t e n by Mark A. Moskowitz, M.D., and 
Michael Osband, M.D., has been published 
by W.W. N o r t o n and Co. of N e w York. I t is a 
comprehensive guide intended to answer 
questions patients may have about medical 
tests and to provide in format ion on the use 
of tests i n physical exams and other settings. 
Dr. M o s k o w i t z is a member of the Section of 
General Medicine and an assistant professor 
of medicine. Dr. Osband, an associate profes-
sor of pediatries, is a member of Univers i ty 
Hospital 's special scientific staff. 
• William B. Kannel, M.D., chief of the Sec-
t i o n of Preventive Medicine and Epidemiol-
ogy and a professor of medicine, has received 
an Honorary Fellow A w a r d f rom the A m e r i -
can College of Preventive Medicine. He was 
eited for his contributions to cardiovascular 
epidemiology and preventive cardiology, and 
for his w o r k as director of the Eramingham 
Heart Study. Dr. Kannel headed the study 
f r o m 1966 to 1979. 
• R. Knight Steel, M.D., chief of the Section 
of Geriatrics and a professor of medicine, is 
president of the Ameriean Geriatrics Society. 
His te rm runs through July of this year. • 
